DNAzyme delivery systems: Getting past first base

Expert Opinion on Drug Delivery

Volumn 6, Issue 2, 2009, Pages 127-138

  Tan, Mei Lin ^b   Choong, Peter F M ^b,c   Dass, Crispin R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Bone and Soft Tissue Sarcoma Service   (Australia)

Author keywords

Chitosan; DNAzyme; Drug delivery system; Gene therapy; Liposome; Oligonucleotide

Indexed keywords

ADAMANTANE DERIVATIVE; ADAMANTANE DIGLUTAMATE POLY(ETHYLENE GLYCOL)GALACTOSE; ADAMANTANE DIGLUTAMATE POLY(ETHYLENE GLYCOL)TRANSFERRIN; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BETA1 INTEGRIN; BETA3 INTEGRIN; CHITOSAN; CYCLODEXTRIN DERIVATIVE; DEOXYRIBOZYME; DRUG CARRIER; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FUGENE 6; IMIDAZOLE; LATENT MEMBRANE PROTEIN 1; LEUCINE ZIPPER PROTEIN; LOCKED NUCLEIC ACID; MACROGOL; MICROSPHERE; POLY(PROPYLENE IMINE); POLYETHYLENEIMINE; POLYGLYCOLIC ACID; POLYLACTIC ACID; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN C JUN; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; MESSENGER RNA; POLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BREAST CARCINOMA; CANCER CELL; CARCINOMA CELL; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; EPITHELIUM TUMOR; EPSTEIN BARR VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; NONHUMAN; PANCREAS CARCINOMA; PATHOGENESIS; PROMYELOCYTIC LEUKEMIA; REVIEW; SUSTAINED DRUG RELEASE; VIRUS CARCINOGENESIS; ANIMAL; CHEMISTRY; DRUG SCREENING; METHODOLOGY; NEOPLASM;

ANIMALS; CARDIOVASCULAR DISEASES; DNA, CATALYTIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; POLYMERS; RNA, MESSENGER;

EID: 66949132992     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902751605     Document Type: Review

References (44)

1. Breaker RR, Joyce GF. A DNA enzyme that cleaves RNA. Chem Biol 1994;1(4):223-9 • Landmark paper on DNAzyme discovery.
2. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997;94(9):4262-6 • A second paper by same lab further defining DNAzyme cleavage kinetics.
3. Lu ZX, Ye M, Yan GR, et al. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther 2005;12(7):647-54 • Paper describing how the EBV protein, LMP1 may present a potential target for DNAzymes as a possible mechanism towards controlling EBV-associated carcinoma.
4. Dass CR, Saravolac EG, Li Y, et al. Cellular uptake, distribution and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 2002;12(5):289-99 • Seminal paper examining the kinetics of uptake of DNAzymes into cultured cells, including distribution and stability in serum.
5. Cairns MJ, Hopkins TM, Witherington C, et al. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotech 1999;17(5):480-6 • Landmark paper defining the effect of choosing mRNA targets based on sequence on DNAzyme cleavage activity in silico.
6. Wu Y, Yu L, McMahon R, et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999;10(17):2847-57 • Seminal paper describing how DNAzymes can downregulate an oncogene and lead to cancer cell growth inhibition.
7. de Bock CE, Lin Z, Itoh T, et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J 2005;272(14):3572-82 • Paper describing the ability of specific DNAzymes to target the uPAR protein, and lead to reduced cell invasion in culture. (Pubitemid 41021170)
8. Fahmy RG, Dass CR, Sun LQ, et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularisation and tumour growth. Nat Med 2003;9(8):1026-32 • Seminal paper looking at the (indirect) in vivo activity of DNAzymes against cancer angiogenesis.
9. Mitchell A, Dass CR, Sun LQ, et al. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor Egr-1. Nucleic Acids Res 2004;32(10):3065-9 • Seminal paper looking at the direct in vivo activity of DNAzymes against tumour growth. (Pubitemid 39022997)
10. Khachigian LM, Fahmy RG, Zhang G, et al. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem 2002;277(25):22985-91 • Original paper describing the discovery of Dz13, one of the most potent DNAzymes reported to date with anticancer activity.
11. Cieslak M, Niewiarowska J, Nawrot M, et al. DNAzymes to beta 1 and beta 3 mRNA downregulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 2002;277(9):6779-87 • Another paper looking at the potential of DNAzymes to inhibit angiogenesis in cultured endothelial cells. (Pubitemid 34953059)
12. Wahlestedt C, Salmi P, Good L, et al. Potent and non-toxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000;97(10):5633-8 • Paper showing that in contrast to PO oligonucleotides, LNA analogues do not cause detectable toxic reactions in rat brain.
13. Fluiter K, ten Asbroek AL, de Wissel MB, et al. In vivo tumour growth inhibition and biodistribution studies of locked nucleic acid(LNA) antisense oligonucleotides. Nucleic Acids Res 2003;31(3):953-62 • An early paper describing the use of LNAs for tumour growth inhibition.
14. Rockwell P, O'Connor WJ, King K, et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1997;94(12):6523-8 • One of several papers describing off-target effects(OTEs) due to PO oligonucleotides.
15. Fahmy RG, Khachigian LM. Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. Nucleic Acids Res 2004;32(7):2281-5 • Seminal paper applying the LNA concept to DNAzymes and showing activity in cultured cells.
16. Schubert S, Gul DS, Grunert HP, et al. RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res 2003;31(20):5982-92 • Interesting paper showing how sequence rearrangments in DNAzyme structure may lead to enhanced activity.
17. Braasch DA, Corey DR. Locked nucleic acid(LNA): fine-tuning the recognition of DNA and RNA. Chem Biol 2001;8(1):1-7 • Review article on LNA technology.
18. Kumar R, Singh SK, Koshkin AA, et al. The first analogues of LNA (locked nucleic acids): phsophorothioate-LNA and 2′-thio-LNA. Bioorg Med Chem Lett 1998;8(16):2219-22 • Chemical paper describing the synthesis of the first chemically modified LNA analogues.
19. Abdelgany A, Wood M, Beeson D. Hairpin DNAzymes: a new tool for efficient cellular gene silencing. J Gene Med 2007;9(8):727-38 • Paper describing the introduction of hairpin technology to the field of DNAzyme research. (Pubitemid 47288830)
20. Beale G, Hollins AJ, Benboubetra M, et al. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridisation-accessible region using the same delivery system. J Drug Target 2003;11:449-56 • A head-to-head comparison of siRNA, ribozyme and DNAzyme in cultured cells. (Pubitemid 38455831)
21. Kabuli M, Yin JA, Tobal K. Targeting PML/RAR alpha transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells. Hematol J 2004;5:426-33 • Another study looking at in vitro anticancer activity of DNAzymes. (Pubitemid 39359279)
22. Liang Z, Wei S, Guan J, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. J Gastroenterol Hepatol 2005;20:1595-602 • Another study looking at in vitro anticancer activity of DNAzymes.
23. Dass CR, Khachigian LM, Choong PFM. c-Jun is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasising model. Mol Cancer Res 2008;6(8):1289-92 • Study showing anti-metastasis activity of a c-jun DNAzyme.
24. Zhang G, Dass CR, Sun LQ, et al. Effect of deoxyribozymes targeting c-Jun on solid tumour growth and angiogenesis in rodents. J Natl Cancer Inst 2004;96:683-96 • Study showing the antiangiogenic activity of a c-jun DNAzyme.
25. Zhang G, Luo X, Sumithran E, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006;25:7260-6 • Paper describing the direct anticancer effect of a c-jun DNAzyme. (Pubitemid 44809091)
26. Dass CR, Freidhuber AM, Khachigian LM, et al. Downregulation of c-Jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008;7(7):1033-6 • A further paper showing antiosteosarcoma activity of Dz13, the c-jun DNAzyme.
27. Santiago FS, Atkins DG, Khachigian LM. Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. Am J Pathol 1999;155:897-905 • Cell culture proof that an egr-1 DNAzyme has activity against cultured vascular smooth muscle cells. (Pubitemid 29426836)
28. Santiago FS, Lowe HC, Day FL, et al. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 1999;154:937-44 • DNAzyme was used as a molecular dissecting tool showing link between egr-1 and FGF-2. (Pubitemid 29122613)
29. Santiago FS, Lowe HC, Kavurma MM, et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999;5:1264-9 • Seminal paper showing link between egr-1 and vascular smooth muscle growth in vitro and in vivo. (Pubitemid 29535603)
30. Bhindi R, Khachigian LM, Lowe HC. DNAzymes targeting the transcription factor Egr-1 reduce myocardial infarct size following ischemia-reperfusion in rats. J Thromb Haemost 2006;4:1479-83 • The egr-1 DNAzyme is shown to have activity against heart disease caused by ischemia.
31. Iversen PO, Nicolaysen G, Sioud M. DNA enzyme targeting TNF-alpha mRNA improves hemodynamic performance in rats with postinfarction heart failure. Am J Physiol Heart Circ Physiol 2001;281:H2211-7 • A DNAzyme targeting TNF-alpha shows improvement of rats that underwent heart failure.
32. Xiang G, Schuster MD, Seki T, et al. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularisation and reduces cardiomyocyte apoptosis after acute myocardial infarction. J Am Coll Cardiol 2005;46:536-41 • PAI-1 downregulation by a specific DNAzyme assists in damaged tissue repair following acute infarction. (Pubitemid 41040299)
33. Xiang G, Seki T, Schuster MD, et al. Catalytic degradation of vitamin D up-regulated protein-1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodelling after myocardial ischemia. J Biol Chem 2005;280:39394-402 • Another study showing benefits to animals suffering from induced heart disease treated with DNAzymes. (Pubitemid 41713897)
34. Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene solcening antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12(6):393-404 • Classic and interesting study comparing the performance of DNAzymes alongside antisense, siRNA and ribozymes.
35. Pun SH, Tack F, Bellocq NC, et al. Targeted delivery of RNA-cleaving DNA enzyme(DNAzyme) to tumour tissue by transferring-modified, cyclodextrin-based particles. Cancer Biol Ther 2004;3(7):641-50 • The use of cyclodextrin-modified particles for transfer of DNAzymes to tumours.
36. Bellocq NC, Pun SH, Jensen GS, et al. Transferrin-containing, cyclodextrin polymer-based particles for tumour-targeted gene delivery. Bioconjug Chem 2003;14(6):1122-32 • A second study showing beneficial effects of a transferrin-mediated targeting of DNAzyme-loaded particles to tumours.
37. Tack F, Bakker A, Maes S, et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes(DNAzymes). J Drug Target 2006;14(2):69-86 • PEI shown to be efficient in transfecting cells with DNAzymes.
38. Tan Y, Liu F, Li Z, et al. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. Mol Ther 2001;3(5 Pt 1):673-82 • A satellite paper looking at sequential delivery of liposomes and plasmids leads to efficient tranfection in vivo with minimal toxicity. (Pubitemid 32509864)
39. Tack F, Noppe M, Van Dijck A, et al. Delivery of a DNAzyme targeting c-myc to HT29 colon carcinoma cells using a gold nanoparticulate approach. Pharmazie 2008;63(3):221-5 • Use of a gold particle to deliver DNAzymes into colon carcinoma cells.
40. Dass CR, Friedhuber AM, Khachigian LM, et al. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencapsul 2008;25(6):421-5 • Lack of toxicity due to a DNAzyme-containing chitosan particulate formulation.
41. Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 1998;432(6):515-9 • Study showing link between c-jun and osteosarcoma patients biopsy specimens.
42. Papachristou DJ, Batistatou A, Sykiotis GP, et al. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 2003;32(4):364-71 • Study showing link between c-jun and osteosarcoma patients biopsy specimens. (Pubitemid 36407536)
43. Fahmy RG, Waldman A, Zhang G, et al. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat Biotechnol 2006;24(7):856-63 • Recent study on Dz13 in non-tumour models.
44. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-4 • Landmark paper on siRNA systemic delivery in primates.